Who are Hutox Inj's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azzalure or Dysport, Botox 100 UNT Injection, OnabotulinumtoxinA 100 UNT [Botox], Botox Cosmetic™, Intradetrusor Botox Injections, Xeomin®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hutox-inj.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hutox Inj — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hutox Inj (Hutox Inj) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin type A. Area: Aesthetics, Neurology.

phase 3 Botulinum toxin type A SNARE complex (acetylcholine release machinery) Aesthetics, Neurology Biologic Live · refreshed every 30 min

Target snapshot

Hutox Inj (Hutox Inj) — Huons Co., Ltd.. Hutox is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hutox Inj TARGET	Hutox Inj	Huons Co., Ltd.	phase 3	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Azzalure or Dysport	Azzalure or Dysport	Galderma R&D	marketed	Botulinum toxin type A	SNARE complex (synaptosome-associated protein)
Botox 100 UNT Injection	Botox 100 UNT Injection	Brigitte Schürch	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox Cosmetic™	Botox Cosmetic™	Carruthers Dermatology Centre	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin type A class)

Merz North America, Inc. · 2 drugs in this class
Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
Brigitte Schürch · 1 drug in this class
Carruthers Dermatology Centre · 1 drug in this class
Galderma R&D · 1 drug in this class
Huons Co., Ltd. · 1 drug in this class
Innovaderm Research Inc. · 1 drug in this class
Lupo Center for Aesthetic and General Dermatology · 1 drug in this class
Merz Aesthetics GmbH · 1 drug in this class
Multiple Sclerosis Center of Northeastern New York · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hutox Inj — Competitive Intelligence Brief. https://druglandscape.com/ci/hutox-inj. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing